Canonical Wnt signaling pathway complex

The Canonical Wnt signaling pathway complex refers to a dynamic, multiprotein assembly responsible for propagating the canonical (β-catenin-dependent) Wnt signal. The core sequence begins with Wnt ligand binding to the Frizzled (FZD) receptor and LRP5/6 co-receptors at the cell membrane, forming the heteromeric "signalosome" that recruits Dishevelled and Axin, disassembling the cytosolic β-catenin "destruction complex" (composed of APC, Axin, GSK3β, CK1α). This results in the stabilization and accumulation of cytoplasmic β-catenin, which translocates to the nucleus and partners with TCF/LEF transcription factors to activate Wnt-responsive genes. The pathway is central to embryonic development, adult tissue homeostasis, and stem cell regulation, and is frequently dysregulated in cancers and regenerative pathologies. Importantly, this "complex" is not a single, structurally discrete therapeutic entity but a functional assembly; most druggable intervention points are individual proteins within this network, not the entire assembly[1][3][4][5][6][7]. Note: No FDA-approved drugs specifically targeting the multiprotein complex as a direct drug target. Most drug discovery efforts target individual components (PORCN, Wnt ligand, Frizzled, LRP5/6, β-catenin, etc.)[3][5][7]. The name "Canonical Wnt signaling pathway complex" refers to a functional multi-protein assembly mediating a signaling pathway, not a single molecular target. Not an approved target name in standard drug or protein databases and is not the typical form for therapeutic targeting. Component proteins (e.g., Frizzled receptor, LRP5/6, β-catenin, APC) are the true drug targets. Therefore, is_incorrect is true: not a single molecule, not a uniquely defined drug target. For proper structured data, the canonical form would be the individual components, or more specifically, names like "Frizzled-7 receptor," "β-catenin," or "LRP6," depending on the intervention point.

Other names

Wnt/β-catenin pathwayWnt receptor signaling complexCanonical Wnt pathwayWnt signalosome (when referring to the receptor complex)Wnt destruction complex (in context of cytoplasmic β-catenin regulation)

Inhibition of Wnt ligand secretion (PORCN inhibitors prevent lipid modification, blocking ligand activity) Disruption of the signalosome (blocking Frizzled or LRP5/6 interactions with Wnt ligand) Promotion of β-catenin degradation (tankyrase inhibitors stabilize axin, enhancing destruction complex function) Inhibition of nuclear β-catenin function (blocking interaction with TCF/LEF transcription factors)